Der er gennemført et åbent, enkeltarms -, multicenter- forsøg med patienter med CML i lymfoid blastfase eller Ph+ ALL, som var resistente eller intolerante over for tidligere imatinibbehandling.
An open-label, single-arm, multicenter study was conducted in patients with lymphoid blast phase CML or Ph+ ALL who were resistant or intolerant to prior imatinib therapy.